openPR Logo
Press release

Exploring the Advancements in Familial Mediterranean Fever Clinical Trials: Anticipating the Arrival of 3+ Innovative Therapies into the Landscape, Insights by DelveInsight

01-12-2024 06:05 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Familial Mediterranean Fever Pipeline

Familial Mediterranean Fever Pipeline

(Albany, USA) DelveInsight's report titled "Familial Mediterranean Fever Pipeline Insight" offers extensive information on more than 3+ companies and over 3+ pipeline drugs in the field of Familial Mediterranean Fever research. The report encompasses detailed profiles of the pipeline drugs for Familial Mediterranean Fever, including information on clinical trials and nonclinical stage products.

For the Familial Mediterranean Fever emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, and route of administration, molecule type, and mechanism of action (MOA). The research on the Familial Mediterranean Fever pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies.

To explore more information on the latest breakthroughs in the Familial Mediterranean Fever Pipeline treatment landscape of the report, click here @ Familial Mediterranean Fever Pipeline Outlook- https://www.delveinsight.com/report-store/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Familial Mediterranean Fever Pipeline Report
• DelveInsight's Familial Mediterranean Fever Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline treatment therapies.
• The leading Familial Mediterranean Fever Companies are working in the market include Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others.
• Promising Familial Mediterranean Fever Pipeline Therapies in various stages of development include Canakinumab (AIN457), Canakinumab, NC-503 (Anti-amyloidotic (AA) Agent), Adalimumab, ACZ885, Apremilast, and others
• Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.
• On Feb 2023, R-Pharm International announced a long-term open-label study is an extension of the core double blind, randomized, placebo-controlled study, CL04018065. It is planned that this study will include no more than 60 patients who completed the core study, where they received blinded therapy.

Familial Mediterranean Fever Overview
Familial Mediterranean fever (FMF) is an inherited auto inflammatory disease characterized by recurrent episodes (attacks) of fever and acute inflammation of the membranes lining the abdomen, joints, and lungs. Some individuals may develop a serious condition known as amyloidosis, in which certain proteins called amyloid accumulates in various tissues of the body.

For further information, refer to the detailed Familial Mediterranean Fever Unmet Needs, Familial Mediterranean Fever Market Drivers, and Familial Mediterranean Fever Market Barriers, click here for Familial Mediterranean Fever Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Familial Mediterranean Fever Emerging Drugs Profile
• Tocilizumab: Roche

Familial Mediterranean Fever Pipeline Therapeutics Assessment
There are approx. 3+ key companies which are developing the therapies for Familial Mediterranean Fever. The companies which have their Familial Mediterranean Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Roche and others.

Request a sample and discover the recent advances in Familial Mediterranean Fever Ongoing Clinical Trial Analysis and Medications, click here @ Familial Mediterranean Fever Treatment Landscape- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Familial Mediterranean Fever Pipeline Therapeutics Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Familial Mediterranean Fever Therapeutics Market include-
Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others

Dive deep into rich insights for drugs for Familial Mediterranean Fever Pipeline, click here @ Familial Mediterranean Fever Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Familial Mediterranean Fever Pipeline Report
• Coverage- Global
• Familial Mediterranean Fever Companies- Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others.
• Familial Mediterranean Fever Pipeline Therapies- Canakinumab (AIN457), Canakinumab, NC-503 (Anti-amyloidotic (AA) Agent), Adalimumab, ACZ885, Apremilast, and others.
• Familial Mediterranean Fever Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Familial Mediterranean Fever Mergers and acquisitions, Familial Mediterranean Fever Licensing Activities @ Familial Mediterranean Fever Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Familial Mediterranean Fever Executive Summary
3. Familial Mediterranean Fever: Overview
4. Familial Mediterranean Fever Pipeline Therapeutics
5. Familial Mediterranean Fever Therapeutic Assessment
6. Familial Mediterranean Fever - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Familial Mediterranean Fever Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. Tocilizumab: Roche
13. Drug profiles in the detailed report…..
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Familial Mediterranean Fever Key Companies
18. Familial Mediterranean Fever Key Products
19. Familial Mediterranean Fever- Unmet Needs
20. Familial Mediterranean Fever- Market Drivers and Barriers
21. Familial Mediterranean Fever- Future Perspectives and Conclusion
22. Familial Mediterranean Fever Analyst Views
23. Familial Mediterranean Fever Key Companies
24. Appendix

Latest Reports launched by DelveInsight:
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market

Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exploring the Advancements in Familial Mediterranean Fever Clinical Trials: Anticipating the Arrival of 3+ Innovative Therapies into the Landscape, Insights by DelveInsight here

News-ID: 3350064 • Views:

More Releases from DelveInsight Business Research

Restrictive Cardiomyopathy Market: Pharma Pipeline Fuels Rapid Expansion by 2024 - DelveInsight
Restrictive Cardiomyopathy Market: Pharma Pipeline Fuels Rapid Expansion by 2024 …
DelveInsight's "Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Restrictive Cardiomyopathy, historical and forecasted epidemiology as well as the Restrictive Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Restrictive Cardiomyopathy, offering comprehensive insights into the Restrictive Cardiomyopathy revenue trends, prevalence, and treatment landscape. The
Heparin Induced Thrombocytopenia Market: Growth Momentum Across 7MM to 2034 - DelveInsight
Heparin Induced Thrombocytopenia Market: Growth Momentum Across 7MM to 2034 - De …
The Heparin-induced Thrombocytopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics. DelveInsight's "Heparin-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Heparin-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Heparin-induced Thrombocytopenia market trends in the United States, EU5
Bronchopulmonary Dysplasia Market: Expanding Revenue Landscape to 2034 - DelveInsight
Bronchopulmonary Dysplasia Market: Expanding Revenue Landscape to 2034 - DelveIn …
DelveInsight's "Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchopulmonary Dysplasia Market Forecast https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key
Erectile Dysfunction Market: Rapid Increment Driven by Innovation by 2034 - DelveInsight
Erectile Dysfunction Market: Rapid Increment Driven by Innovation by 2034 - Delv …
DelveInsight's "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology as well as the Erectile Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Erectile Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Erectile Dysfunction Market Forecast https://www.delveinsight.com/sample-request/erectile-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Familial

Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the
Familial Hypercholesterolemia Market Detailed Industry Report Analysis 2025-2034
Introduction Familial Hypercholesterolemia (FH) is a genetic disorder characterized by dangerously high cholesterol levels, often leading to early cardiovascular disease. Affecting millions worldwide, FH is frequently underdiagnosed and undertreated. However, advances in biologics, small-molecule therapies, and diagnostics are creating new opportunities to manage this high-risk condition effectively. According to Exactitude Consultancy, the Familial Hypercholesterolemia Market was valued at USD 10 billion in 2024 and is projected to reach USD 20 billion by
Familial breast cancer treatment market Impact of Covid-19
Description FAMILIAL BREAST CANCER TREATMENT market research report is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Data Bridge Market Research analyses that the familial breast cancer treatment market was valued at USD 1.93 billion in 2021 and is expected to reach USD 5.17 billion by 2029, registering a CAGR of 13.10% during the forecast period of 2022 to 2029.
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. Download the sample report at: https://www.pharmaproff.com/request-sample/1025 A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke. Download the sample report @ https://www.pharmaproff.com/request-sample/1135 A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or